Skip to main content

Advertisement

ADVERTISEMENT

Interactive Features

Quiz
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
08/22/2024
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...
True or False: According to...
08/22/2024
Oncology

Advertisement

Quiz
02/28/2024
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...
True or False: Momelotinib...
02/28/2024
Oncology
Quiz
02/27/2024
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...
The addition of parsaclisib to...
02/27/2024
Oncology

Advertisement

Quiz
02/13/2024
What was the main finding of a phase 2 trial on the 5-year survival and efficacy of ropeginterferon among patients with low-risk polycythemia vera?
What was the main finding of a phase 2 trial on the 5-year survival and efficacy of ropeginterferon among patients with low-risk polycythemia vera?
What was the main finding of a...
02/13/2024
Oncology
Quiz
01/31/2024
What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?
What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?
What was the key finding of a...
01/31/2024
Oncology
Quiz
01/31/2024
True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...
True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...
True or False: Findings from a...
01/31/2024
Oncology

Advertisement

Quiz
01/16/2024
True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.
True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.
True or False: Interim results...
01/16/2024
Oncology

Advertisement